Table 1.
Sociodemographic and clinical characteristics of the sample
| Sociodemographic - mean (SD) | No recent cannabis use (n = 138) |
Occasional recent cannabis use (n = 29) |
Frequent recent cannabis use (n = 47) |
Statistics | p-value | Cohen’s d |
|---|---|---|---|---|---|---|
| Age | 34.46 (8.20) | 33.11 (8.12) | 30.58 (7.50) | F = 3.47 | .033 | .316 |
| Income per month (US$) | 1556.64 (1100) | 1870.07 (1332) | 1349.01 (842) | F = 2.01 | .136 | .241 |
| Days of drug consumption last month – mean (SD) | ||||||
| Tobacco | 17.32 (9.85) | 19.79 (8.31) | 20.25 (8.01) | F = 2.17 | .116 | .250 |
| Alcohol | 6.76 (9.41) | 8.21 (8.71) | 7.74 (9.25) | F = .407 | .666 | .108 |
| Cannabis | 0 (0) | 1.97 (1.21) | 21.02 (5.92) | F = 692 | >.001 | 4.46 |
| Cocaine | 16.14 (8.52) | 17.62 (6.91) | 17.34 (8.06) | F = .627 | .539 | .134 |
| Years of regular drug use – mean (SD) | ||||||
| Tobacco | 17.62 (9.13) | 16.97 (10.24) | 15.88 (8.01) | F = .495 | .610 | .119 |
| Alcohol | 4.54 (7.13) | 5.39 (8.03) | 4.89 (5.65) | F = .189 | .828 | .074 |
| Cannabis | 3.62 (5.85) | 7.86 (9.43) | 13.36 (8.47) | F = 30.89 | >.001 | .944 |
| Cocaine | 8.45 (5.79) | 8.23 (6.51) | 8.18 (7.20) | F = .037 | .964 | .033 |
| Motivation for detoxification treatment - mean (SD) | ||||||
| Motivation towards treatment success | 3.80 (0.58) | 3.76 (0.62) | 3.86 (0.55) | F = .416 | .880 | .110 |
| Motivation for abstinence of all drugs | 3.71 (0.80) | 3.76 (0.79) | 3.41 (1.20) | F = .860 | .425 | .157 |
| Medication use during detoxification - % (n) | 64.5 (89) | 62.1 (18) | 46.8 (22) | χ2 = 4.62 | .099 | - |
| Past treatments - mean (SD) | ||||||
| Number of life-time treatments for alcohol/drugs | 4.79 (4.33) | 4.10 (2.62) | 6.64 (7.05) | F = 3.20 | .043 | .304 |
| Number of life-time inpatient treatments | 3.96 (3.56) | 3.55 (2.64) | 5.32 (5.87) | F = 1.59 | .097 | .214 |
Note: Between group comparisons performed by ANOVA or chi-square test; Medication use during inpatient treatment, participants had prescribed symptomatic cocaine detoxification protocol, including neuroleptics, analgesics, antidepressants and mood stabilizers; CSSA, Cocaine Selective Severity Assessment; BDI-II, Beck Depressive Inventory. Cohen’s d effect size estimates.